Eikon Therapeutics (NASDAQ:EIKN) Stock Gets Price Target Cut from Morgan Stanley

Eikon Therapeutics (NASDAQ:EIKN – Free Report) had its target price decreased by Morgan Stanley to $30.00 in a research note issued to investors on Wednesday morning,Benzinga reports. Morgan Stanley currently has an overweight rating on the stock.

EIKN has been the topic of several other reports. Wall Street Zen raised Eikon Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 14th. HC Wainwright began coverage on Eikon Therapeutics in a report on Friday, October 16th. They set a “buy” rating and a $23.00 target price on the stock. Wedbush reduced their target price on Eikon Therapeutics from $5.00 to $4.00 and set an “underperform” rating on the stock in a report on Friday, August 14th. Cantor Fitzgerald reissued an “overweight” rating on shares of Eikon Therapeutics in a research report on Friday, August 21st. Finally, Mizuho upgraded Eikon Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 16th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $24.33.

Check Out Our Latest Report on Eikon Therapeutics

Eikon Therapeutics Stock Down 0.4%

Shares of EIKN opened at $4.74 on Wednesday. The firm’s 50-day moving average price is $7.02 and its 200-day moving average price is $9.91. Eikon Therapeutics has a 1-year low of $4.72 and a 1-year high of $17.40.

Eikon Therapeutics (NASDAQ:EIKN – Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($1.59) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.74) by $0.15. Sell-side analysts anticipate that Eikon Therapeutics will post -6.96 earnings per share for the current year.

Insider Activity at Eikon Therapeutics

In other Eikon Therapeutics news, major shareholder Group Iv Gp Lp Column bought 89,200 shares of Eikon Therapeutics stock in a transaction dated Thursday, September 3rd. The shares were purchased at an average cost of $11.56 per share, with a total value of $1,031,152.00. Following the transaction, the insider directly owned 89,200 shares of the company’s stock, valued at $1,031,152. This represents a ? increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. BlackRock Inc. lifted its holdings in shares of Eikon Therapeutics by 29.0% during the second quarter. BlackRock Inc. now owns 4,281,425 shares of the company’s stock valued at $55,873,000 after purchasing an additional 962,046 shares during the last quarter. Regents of The University of California bought a new stake in shares of Eikon Therapeutics in the 3rd quarter worth approximately $5,106,000. State Street Corp bought a new stake in shares of Eikon Therapeutics in the 2nd quarter worth approximately $4,621,000. Parkman Healthcare Partners LLC bought a new stake in shares of Eikon Therapeutics in the 2nd quarter worth approximately $3,341,000. Finally, StepStone Group LP boosted its position in shares of Eikon Therapeutics by 32.4% in the 3rd quarter. StepStone Group LP now owns 523,467 shares of the company’s stock worth $4,209,000 after purchasing an additional 128,127 shares in the last quarter.

Eikon Therapeutics Company Profile

(Get Free Report)

Eikon Therapeutics is a biopharmaceutical company focused on discovering and developing medicines for serious diseases, including cancer. The company uses advanced imaging, computational biology and drug-discovery methods to study how proteins behave in living cells and identify potential therapeutic targets. Founded in 2019 by Roger Perlmutter, a former head of Merck Research Laboratories, Eikon is based in California. Its work is centered on research and development; the company is not known for marketed medicines.

Further Reading

Analyst Recommendations for Eikon Therapeutics (NASDAQ:EIKN)

Receive News & Ratings for Eikon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eikon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.